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Abstract.  We have explored the hypothesis that hyper- 
trophy of vascular smooth muscle cells may be regu- 
lated,  in part,  by growth inhibitory factors that alter 
the pattern of the growth response to serum mitogens 
by characterizing  the effects of the potent growth in- 
hibitor,  transforming  growth factor-[I  (TGF-13),  on both 
hyperplastic and hypertrophic growth of cultured rat 
aortic smooth muscle cells. TGF-13 inhibited serum- 
induced proliferation of rat aortic smooth muscle cells 
(EDs0  =  2 pM); this is consistent with previously 
reported observations in bovine aortic smooth muscle 
cells (Assoian et al.  1982. J.  Biol.  Chem.  258:7155- 
7160).  Growth inhibition  was due in part to a greater 
than twofold increase in the cell cycle transit time in 
cells that continued to proliferate in the presence of 
TGF-13. TGF-I~ concurrently induced cellular hyper- 
trophy as assessed by flow cytometric analysis of cel- 
lular protein content (47 % increase) and forward angle 
light scatter (32-50%  increase),  an index of cell size. 
In addition to being time and concentration dependent, 
this hypertrophy was reversible.  Simultaneous flow 
cytometric evaluation of forward angle light scatter and 
cellular DNA content demonstrated that TGF-I~-in- 
duced hypertrophy was not dependent on withdrawal 
of cells from the cell cycle nor was it dependent on 
growth arrest of cells at a particular point in the cell 
cycle in that both cycling cells in the G2 phase of the 
cell cycle and those in Gm were hypertrophied with re- 
spect to the corresponding ceils in vehicle-treated  con- 
trols.  Chronic treatment  with TGF-I~ (100 pM, 9 d) was 
associated with accumulation of cells in the G2 phase of 
the cell cycle in the virtual absence of cells in S 
phase,  whereas subsequent removal of TGF-I~ from 
these cultures was associated with the appearance of a 
significant fraction of cycling cells with >4c DNA 
content,  consistent with development of tetraploidy. 
Results of these studies support a  role for TGF-I~ in 
the control of smooth muscle cell growth and  suggest 
that at least one mechanism whereby hypertrophy and 
hyperploidy may occur in this,  as well as other cell 
types, is by alterations  in the response to serum mito- 
gens by potent growth inhibitors  such as TGF-I~. 
C 
ELLULAR enlargement  or hypertrophy plays a promi- 
nent  role in  the postnatal  growth of many  tissues, 
as well as in physiological  and pathological  hyper- 
trophy of a variety  of tissues (4).  However, relatively  little 
is known  regarding  the mechanisms that  control cell size. 
Even less is known concerning the control mechanisms  for 
the DNA endoreduplication and polyploidy that  often ac- 
companies cellular hypertrophy,  although  its occurrence is 
widespread in eukaryotic cells in vivo, occurring in termi- 
nally differentiated  cardiac myocytes (14, 15, 29), and neu- 
rons (22), as well as in nonterminally  differentiated  hepato- 
cytes (8),  smooth muscle cells (10, 23, 30), and other cell 
types (see review by Brodsky and  Uryvaeva  [8]). 
Our laboratory has been particularly interested in the me- 
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dial hypertrophy of smooth muscle that develops in large at- 
miles of hypertensive  animals  and humans (17, 23, 30) and 
has been implicated in the pathogenesis  of this disease.  Aor- 
tic hypertrophy is characterized  by enlargement  of existing 
smooth muscle cells with little or no change in cell number 
and is accompanied by development of polyploidy in a large 
fraction  of smooth muscle cells (10, 23, 24, 30).  Develop- 
ment of polyploidy in these cells does not appear to be due 
to an inherent  loss in the capacity of cells to divide since 
tetraploid cells can be induced to proliferate in vitro in serum 
containing  medium after isolation  from intact  vessels and 
separation on the basis of DNA content using a fluorescence 
activated cell sorter (19) or in vivo by subjecting vessels that 
contain polyploid cells to balloon embolectomy-induced in- 
jury (Owens,  G. K., manuscript in preparation).  This sug- 
gests that the growth response of smooth muscle cells, i.e., 
hypertrophy vs. hyperplasia, is a function of the nature of the 
growth stimulus.  However, the precise factors  that  control 
hypertrophic vs. hyperplastic growth of smooth muscle cells 
©  The Rockefeller University Press, 0021-9525/88/08/771/10 $2.00 
The Journal of Cell Biology, Volume 107, August 1988 771-780  771 are not known and virtually nothing is known regarding the 
mechanisms  responsible for development of polyploidy in 
this cell. 
There are several possible mechanisms to explain develop- 
ment of cellular hypertrophy. One hypothesis is that hyper- 
trophy results from incomplete growth stimulation whereby 
the cell receives signals for the increased cell mass and DNA 
replication associated with cell cycle progression but not for 
cell division (5, 18). An alternative hypothesis, and the prin- 
cipal focus of the present study, is that cellular hypertrophy 
may be regulated,  in part, by growth inhibitory factors that 
alter the pattern of the growth response to mitogens resulting 
in incomplete  growth  stimulation.  An attractive  candidate 
for a substance that might elicit the latter response in smooth 
muscle  cells  is  transforming  growth  factor-13 (TGF-13). ~ 
This 25-kD polypeptide homodimer (2) has been shown to 
be a potent growth inhibitor for vascular smooth muscle cells 
(3) as well as a variety of other anchorage-dependent  cells 
(32), and it has been suggested that it may be a mediator of 
smooth muscle cell growth in vivo during wound repair and 
atherogenesis (3, 12). Of particular interest, treatment of pri- 
mary  cultures  of renal  proximal  tubule  cells  with  BSC-1 
growth inhibitor,  which has similar biological properties as 
TGF-[I,  is associated with development of cellular  hyper- 
trophy (16). 
The principal aim of the present study was to explore the 
possible mechanisms  for development of hypertrophy  and 
hyperploidy in vascular smooth muscle cells by characteriz- 
ing the role of TGF-13 in control of hyperplastic growth of 
cultured  rat  aortic  smooth  muscle  cells,  and  determining 
whether  TGF-13-induced  growth  inhibition  was associated 
with development of cellular hypertrophy and/or accumula- 
tion of cells with tetraploid DNA content. 
Materials and Methods 
Cell Culture 
Rat thoracic aortic smooth muscle cells were isolated and cultured as previ- 
ously described (25)  with the following modifications: (a)  150-175-g  rats 
were used instead of 200-225-g  rats;  and (b) the following enzymes in 
Hanks' balanced salt solution were used for cell isolations:  1 mg/ml col- 
lagenase (type II, 158 U/mg), 0.25 mg/ml elastase (type I, 3 U/rag), 1 mg/ 
ml  soybean  trypsin  inhibitor  (all  from  Cooper  Biomedical  Inc.,  Mal- 
vern, PA). 
Cells were harvested for passaging at confluency ('~5-d intervals) with 
a trypsin-EDTA (0.05% trypsin, 0.02%  EDTA, Gibeo Laboratories, Grand 
Island, NY) solution and plated at 2-5  ×  103 eells/cm  2. Ceils were grown 
in either: (a) a  1:1 mixture of Dulbecco's modified Eagle's medium (DME, 
Gibco Laboratories) and Ham's F12 medium (Gibco Laboratories), contain- 
ing 10% fetal calf serum (FCS, Hyclone Laboratories, Logan, LIT) (desig- 
nated DF10);  or (b) Medium 199 plus either 5% or 10% FCS; or (c) DME 
and Ham's F-12 (1:1) containing insulin (5  x  10  -7 M), transferrin (5  p.g/ 
ml), and ascorbate (0.2 mM) all from Sigma Chemical Co. (St. Louis, MO), 
designated serum-free medium (SFM). All media were supplemented with 
L-glutamine (0.68 raM, Sigma Chemical Co.), penicillin (100 U/ml), and 
streptomycin (100 ~tg/ml).  The SFM has been shown to maintain smooth 
muscle cells in a quiescent, noncatabolic state for extended periods of time 
and to promote expression of smooth muscle ceil-specific contractile pro- 
teins (25). Cell cultures were incubated at 37°C in a humidified atmosphere 
of 5 % CO2/95 % air with media changes every 2-3 d. 
1.  Abbreviations  used  in  this paper:  FALS,  forward angle light scatter; 
SFM, serum-free medium; T¢, cell cycle transit time; TGF-[3, transforming 
growth factor-13. 
Growth Curves 
Cultures  were washed with a  calcium- and  magnesium-free phosphate- 
buffered saline (PBS:  NaCI  137 mM,  Na2HPO4  8.1  raM,  KC! 2.7  mM, 
KH2PO4  1.5  mM,  pH  7.4)  harvested with  trypsin-EDTA,  diluted  with 
0.85%  NaCI (Columbia Diagnostics Inc,, Camden, SC), and counted on an 
Electrozone Celloscope (Particle Data Inc., Elmhurst, IL) with orifice size 
of 95 lam and sample volume of 500 lxl. Triplicate wells were counted for 
each group at every time point. 
[JH]Thymidine Autoradiography 
For determination of the fraction of cells in the S phase of the cell cycle, 
cultures were pulse labeled with [3Hlthymidine (1  gCi/ml, 6.7 Ci/mmol, 
New England Nuclear, Boston, MA) for 1 h in regular culture medium. 
Cultures were then washed twice with PBS, fixed in 2 % glutaraldehyds for 
5 min, dehydrated, and coated with Kodak NTB2 emulsion (diluted 1:1 with 
distilled water). Dishes were exposed for 5-7 d at 4°C and then developed 
in D-19 (Eastman Kodak Co., Rochester, NY), fixed with Rapid-Fix (East- 
man Kodak Co.) and stained with hematoxylin. The percentage of cells syn- 
thesizing DNA was determined by counting the number of labeled cells 
(nuclei) in a random sample of at least 1,000 cells from each dish. Triplicate 
dishes were analyzed for each group. 
Determination of labeling indices over a 72-h labeling period (e.g., see 
Table I) was done as above with the exception that cells were labeled con- 
tinuously with 0.01 I.tCi/ml of [3H]thymidine  (renewed daily). 
[JH]Thymidine Incorporation 
Relative  rates  of  DNA  synthesis  were  assessed  by  determination  of 
[3H]thymidine  incorporation into trichloroacetic acid (TCA)-precipitable 
material.  Cells  were  pulsed  for  2  h  with  [3H]thymidine  (2  gCi/ml), 
washed with PBS followed by one wash with 10% (wt/vol) cold TCA at 4°C 
(10 min), and one wash with 10% TCA at 22°C. Cells were then dissolved 
in 0.5 N NaOH, placed in RediSolve EP (Beckman Instruments, Inc., Palo 
Alto, CA), and counted. Quadruplicate dishes were analyzed per sample 
point. 
Flow Microfluorimetric Analysis 
of  CeUular DNA, Forward  Angle Light Scatter (FALS), 
and Protein Content 
Cultures were washed with PBS and harvestexi using the trypsin-EDTA solu- 
tion described above.  Samples were divided for protein and DNA analysis 
and then centrifuged (113 g, 6 min). For the protein staining, cells were fixed 
in 75%  (vol/vol) methanol in PBS on ice for 30 min, centrifuged (113 g, 
6  min),  stained with fluorescein isothiocyanate (FITC,  75  ng/ml,  Sigma 
Chemical Co.; 0.5 M NaHCO3,  pH 8) on ice for 30 min, then cemrifuged 
(113 g, 6 min) and resuspended in 0.85%  (wt/vol) NaC1 (11). For the mea- 
surement of cellular DNA and FALS, cells were fixed in methanol as above, 
centrifuged (113 g, 6 min) and stained with Hoechst 33258 (Sigma Chemical 
Co.) (0.58 I~g/ml; NaCI 145 raM; "Iris 100 raM, pH 7.4). All samples were 
kept on ice until analyzed on a Coulter Epics V fluorescence-activated cell 
sorter (Coulter Electronics Inc., Hialeah, FL). The Epics V was calibrated 
in terms of fluorescent signals and  FALS using fluorescent polystyrene 
beads (9.7 gm diam, Coulter Electronics Inc.) in order to normalize ma- 
chine settings between different sample runs. Cell clumping was <1% based 
on analysis of peak versus integrated fluorescence. Statistical evaluation of 
FALS and protein data was done using the standard statistical software pack- 
age provided by Coulter Electronics Inc. This involved selecting minimal 
and maximal values that encompassed the entire cell population and calcula- 
tion of the mean and standard deviation for each individual sample. Cell 
cycle fitting of DNA histograms was done by modification of the method 
of Dean and Jett (13) as previously described (23). 
Preparation of Transforming Growth Factor-~ 
TGF-13 was prepared from outdated human platelets as previously described 
(2). Fractions containing TGF-I~ from Bio-Gel P-60 chromatography with 
1 M acetic acid containing 6 M urea as an eluent were pooled and TGF-I~ 
was further purified by high-performance liquid chromatography (HPLC) 
using a reverse-phase C18 column (SynChropak RP-P, 4.6 x  250 mm, Syn- 
Chrom, Inc., Linden, IN) and water/acetonitrile solvent system containing 
0.1% (vol/vol) TCA. Rechromatography of the purified TGF-I3 on HPLC in- 
dicated the protein to be homogeneous and the protein concentration was 
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Figure 1.  Serum dependence  of TOF-I~-induced growth inhibi- 
tion. Ceils were plated at 3 x  10Vcm  2 in Medium 199 containing 
10% FCS for 24 h to facilitate cell attachment  and growth,  and 
then switched to Medium  199 plus the FCS concentrations  shown 
for 3 d before addition of TGF-I~ (100 pM) or vehicle (1 mg/ml 
BSA).  Cell  counts  were determined  in  triplicate  wells  of each 
group after growth in each of the respective media for 6 d. Media 
were changed at 2-d intervals and fresh TGF-I~ or vehicle added. 
Values shown are mean +  SD. 
determined by amino acid analysis using the Pico-Tag method (Waters As- 
sociates, Milford, MA) (7). The biological activity of purified TGF-13 was 
assessed using a soft agar assay with normal rat kidney target cells (2). The 
EDs0 was 10 pM. 
Statistics 
All results were analyzed by either Student's t test or an analysis of variance 
combined with Newman-Keuls multiple range test for intergroup compari- 
sons. Probabilities of 0.05 or less were considered statistically significant. 
All experiments were repeated at least in duplicate. Values reported in the 
text are means plus or minus standard deviation (SD). 
Results 
TGF-~-lnduced Inhibition of  CeU Growth 
Initial  studies  demonstrated  that  the  effects of TGF-I3  on 
proliferative growth of rat aortic smooth muscle cells were 
dependent on serum concentration. After growth for 6 d, cell 
number  was  reduced  by  36%  in  TGF-13-treated  cultures 
vs. controls in cells grown in 5% FCS, whereas only a 20% 
reduction was observed in cells grown in 10% FCS (Fig.  1). 
TGF-I~ had no significant effect on cell number in quiescent 
cultures maintained in 1% FCS. Since the percent reduction 
in cell number was greater in cells grown in 5 % FCS than 
in  10% FCS, all subsequent experiments, unless otherwise 
noted,  were carried out using 5 % FCS. 
TGF-13 was  extremely  potent  in  inhibiting  cell  growth 
showing maximal inhibition at a concentration of 20 pM, and 
an  EDs0  of 2  pM  (Fig.  2).  Mean  cell-doubling  times  for 
TGF-13 (20 pM) and vehicle-treated control cultures were 33 
and 22 h, respectively, over the 3-d treatment period. To en- 
sure that TGF-[I did not reduce cell number simply by induc- 
ing  increased cell death or detachment,  growth inhibition 
was also assessed by determination of [3H]thymidine incor- 
poration  into  TCA-precipitable  material  at  22-24  (1  d), 
46-48 (2 d), and 70-72  (3 d) h after addition of TGF-13 or 
vehicle, and by determination of the fraction of cells in the 
S phase of the cell cycle by flow cytometric analysis of cellu- 
lar DNA content. Consistent with cell number data, the rate 
of cell proliferation as judged by [3H]thymidine incorpora- 
tion was decreased by 40% after 1 d of TGF-[I treatment, and 
by 70-75 % after 2 and 3 d of treatment. Maximal inhibition 
of [3H]thymidine incorporation was seen at TGF-[I concen- 
trations of 20 pM or greater. Although significant inhibition 
was observed with as short as 24 h of TGF-[3 treatment, max- 
imal inhibition required  2  d  or more of TGF-13 treatment. 
Results of flow cytometric assays (not shown) showed a re- 
duction in the fraction of cells in S phase in TGF-I~-treated 
cultures as compared to controls, which was evident as early 
as  1 d after initiation of treatment. 
Effects of TGF-~ on Cell Cycle Transit IIme 
TGF-l~-induced growth inhibition was further characterized 
by addressing the following two questions: (a) is there a sub- 
fraction of cells that either fail to replicate their DNA or 
replicate it at extremely slow rates in the presence of TGF-13? 
and  (b)  is the  cell cycle transit  time (To) altered  in  those 
cells that continue to replicate in the presence of TGF-I3? In 
this experiment cells were plated in Medium 199 containing 
10%  FCS for 24 h and then switched to Medium  199 plus 
5 % FCS with or without 100 pM TGF-13 for a pretreatment 
period of either 1 or 2 d. Cells were then grown in the con- 
tinuous  presence  of 0.01 lxCi/ml  [3H]thymidine  (renewed 
daily) for a period of 72 h (this exceeds the doubling times 
of both control and TGF-13-treated cultures), either between 
1 and 4 d or 2 and 5 d after initiation of TGF-I~ treatment. 
Culture media were changed and fresh TGF-I~ added at 2-d 
intervals. Cell counts were determined in replicate dishes at 
the beginning and end of the labeling period and autoradiog- 
raphy was performed at the end of the experiment to deter- 
mine the  fraction of [3H]thymidine-labeled and  unlabeled 
cells.  The fraction of cells present at the initial time point 
(i.e., the time of addition of [3H]thymidine) that replicated 
their DNA over the 72-h labeling period was calculated as: 
one minus the ratio of unlabeled final cell number/initial cell 
number.  Results (Table I) demonstrated that a significantly 
smaller  fraction  of TGF-fi-treated  cells  as  compared  to 
vehicle-treated  cells  replicated  their  DNA  over the  72-h 
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Figure 2.  Concentration  dependence  of TGF-13-induced growth 
inhibition  as  assessed  by analysis  of cell  number.  Cells  were 
plated at 3  x  103/cm  2 in Medium  199 containing  10% FCS for 
24 h to facilitate cell attachment  and growth,  and then switched 
to Medium 199 containing 5% FCS with or without TGF-I~ at the 
concentrations  indicated  for 3 d.  Control  cultures  were treated 
with TGF-I~  vehicle. Cell number was assessed at the time of addi- 
tion of TGF-13 or vehicle and at 3 d. Values shown are mean -I- 
SD, n =4. 
Owens et al. Hypertrophy Induced by Transforming Growth Factor-fl  773 Table I. Growth Fraction and Cell Cycle Time of TGF-~-(I  OO  pM) and Vehicle-treated Smooth Muscle Cell Cultures 
~: Cell  number  Percent Labeled  Percent cycling  Percent increase  Doubling time 
* Duration of  cells  cells  in cycling cells  of cycling 
Group  pretreatment  Initial  Final  (final)  (initial)§  (1~2  d)l[  cells (i.e.,  To) 
d  per cm  z  h 
TGF-I~  1  5,384  +  200  8,024  +  50  80.3  +  1.9  71  45  45  2  7,024 +  284  8,896 +  580  71.3  +  0.6  64 
Vehicle  1  5,936 +  364  12,840  5- 206  93.4 5- 0.3  86  126  20  2  12,536 5- 328  19,136  5- 364  94.2  5-  1.0  91 
Values shown are means +  SE. 
* Duration of treatment with TGF-I~ or vehicle before initiation  of [3H]thymidine  labeling.  [3H]thymidine  labeling was then done for 72 h with continuous treat- 
merit with TGF-[I or vehicle. 
¢ Cell number was determined at the time of initiation of [3H]thymidine  labeling and 72 h thereafter. Thus, for the  l-d pretreatment groups the initial  and final 
cell counts were done on days 1 and 4, respectively, whereas for the 2-d pretreatment groups initial  and final cell counts were done on days 2 and 5, respectively. 
Cell count samples were treated  identically  as samples used for autoradiography including addition of [3H]thymidine. 
§ Percentage of cells present at time 0  (i.e.,  initial  time) which are labeled after growth in the continuous presence of [3H]thymidine  (0.01  p.Ci/ml)  for 72 h. 
II This was calculated  as the change in cell number between days  1 and 2 divided  by the number of cycling cells present (i.e.,  mean cycling fraction at  1-2 d 
x  initial  cell  count). This calculation assumes that all  new cells must be derived from the cycling fraction and that cell  death was negligible. 
labeling period, indicating that there is a substantial fraction 
of cells that either do not cycle or cycle at extremely slow 
rates in the presence of TGF-13. Note that we cannot defini- 
tively conclude that these cells have actually withdrawn from 
the cell cycle since we have not demonstrated that these cells 
might not eventually replicate their DNA with further exten- 
sion of the labeling period. 
To address whether TGF-13 also influenced cell cycle tran- 
sit times  in cells that were observed to proliferate during 
TGF-I~ treatment, data were further analyzed by calculating 
both the fractional increase and doubling time of the cycling 
fraction of cells  between  1 and 2  d  of treatment  with ei- 
ther vehicle or TGF-[3. Note that this estimate of doubling 
time for the cycling fraction of cells provides an estimate of 
the mean interdivision time of cells (i.e.,  To) for each of the 
growth conditions.  Results demonstrated (Table  I) that the 
mean interdivision time was more than doubled in cultures 
treated with TGF-13 (To  =  44.7 h) as compared to control 
(T~  =  20.3 h). 
TGF-~-induced Cellular Hypertrophy 
Marked  changes  in  cellular  morphology were  evident  in 
TGF-13-treated  cultures in the growth inhibition studies de- 
Figure 3. Phase micrograph of rat aortic smooth muscle cells after 
treatment  with  TGF-I3 (right) or vehicle  (left) for  3 d  in  the 
presence  of 5%  FCS.  Initial experimental conditions were  as 
described in Fig. 2. 
scribed above (Fig.  3). The most notable change was an ap- 
parent increase in cell size. To assess this on a more quantita- 
tive basis, and to ensure that it did not simply represent cell 
spreading, cell size was assessed by flow cytometric analysis 
of both FALS, a measure of relative cell size,  and cellular 
protein content. In these experiments,  smooth muscle cells 
were plated in 10% FCS for 24 h and then switched to 5% 
FCS with or without 100 pM TGF-13 for 3 d.  Results (Fig. 
4) showed a significant rightward shift in both FALS, as well 
as protein content histograms in TGF-13-treated  cultures as 
compared to vehicle-treated controls. TGF-13 was extremely 
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Figure 4.  TGF-13-induced increases in relative cell size (FALS) 
and relative protein content as determined by flow microfluorime- 
try.  Cells were plated in Medium 199 containing 10%  FCS for 
24 h and then switched to Medium 199 containing 5% FCS and 
either 100 pM TGF-I3  or vehicle (1 mg/ml BSA). Cells were treat- 
ed  for 3 d and then harvested for flow cytometric analysis of 
FALS and relative protein content as described in Materials and 
Methods.  Between 5,000  and  10,000 cells  were  analyzed per 
sample. 
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Figure 5.  Concentration dependence of TGF-13-induced  smooth 
muscle cell  hypertrophy.  Cells  were plated  at  3  x  103/cm  2 in 
Medium 199 containing 10% FCS for 24 h and then switched  to 
Medium 199 containing 5% FCS plus either vehicle or TGF-I~ at 
the concentrations indicated.  Cells were treated for 3 d and cellu- 
lar hypertrophy assessed by flow cytometric analysis of FALS. 
Mean FALS values were determined for each individual  sample 
from histograms  such  as  those  displayed  in  Fig.  5,  and  these 
values used  for calculation of the group means (:t:SD, n  =  3) 
shown. 
160- 
£  14o.  ._  .,.-. 
c 
_  O 
o 
{ 
t 
Duration of TGFbeta Treotment (doys) 
Figure 6.  Time course of TGF-13-induced  cellular hypertrophy. 
Cells were plated as described in Fig. 5 and then treated with 100 
pM TGF-I~ or vehicle for the times indicated.  Culture media, as 
well  as TGF-I~ and vehicle,  was replaced at 2-d intervals.  Al- 
though flow cytometer settings  (i.e.,  laser power, gain settings, 
etc.)  were  normalized  as  much  as  possible  between  runs  on 
separate days, FALS data are expressed as a percentage of the cor- 
responding  vehicle-treated  control  to  normalize  for day-to-day 
fluctuations  in  machine  performance.  Triplicate  samples  were 
analyzed per time point per group. In some cases, the SD bars are 
less than the symbol size. 
potent in inducing cellular hypertrophy causing a  47 %  in- 
crease mean cellular protein content and a 32-50 % increase 
(range  of means  from  four  independent  experiments)  in 
FALS compared to controls  after  treatment  with  100 pM 
TGF-[~ for 3 d. This cellular hypertrophy showed a steep con- 
centration dependence with near-maximal effects after 3 d of 
treatment at a concentration of 100 pM and an EDso  =  20 
pM (Figs. 5 and 6). Small but significant increases in relative 
cell size occurred after 1 d of 'I'GF-[3 treatment (Fig. 6), al- 
though the most rapid increase in relative cell size occurred 
between  1 and  3  d  of treatment.  Hypertrophy was  nearly 
maximal at 3 d, but there was an additional  small increase 
in cell  size between  3 and 9  d. 
Reversal of TGF-#-induced 
Smooth Muscle Hypertrophy 
To assess  the  reversibility  of TGF-l~-induced  hypertrophy 
cells were first treated for 3 d with 100 pM TGF-13 to induce 
near maximal hypertrophy, and then washed and switched to 
Medium 199 +  5  %FCS alone for 6 d. Relative cell size was 
then measured by flow cytometric evaluation of FALS.  Re- 
sults  demonstrated that TGF-I~-induced increases  in FALS 
were  reduced  by >90%  following removal  of TGF-I3 and 
growth in 5 %  FCS alone for 6  d. 
Cell Cycle Dependence of TGF-~-induced 
Smooth Muscle Cell Hypertrophy 
Since TGF-[3-induced growth inhibition was only partial,  it 
was important to determine whether TGF-13-induced cellular 
hypertrophy was restricted to cells which were blocked at a 
particular point in the cell cycle. This was assessed by simul- 
taneous analysis of cellular DNA content and FALS. A sum- 
mary of comparisons of mean  FALS of control and  TGF- 
13-treated cells in either  the Go-G~ or G2 phase of the cell 
cycle is  presented  in  Fig.  7.  Results  demonstrated that for 
each of the concentrations examined, the increase in cell size 
induced by TGF-[~  was the same for cycling cells in G2 as 
for cells in Go-Go. Note that,  although some of the cells in 
G2 may not be cycling, a considerable fraction must be cy- 
cling,  since  a  substantial  fraction  of  cells  continue  to 
proliferate at this time in the presence of TGF-13 (see Fig. 2). 
Thus, TGF-fi-induced cellular hypertrophy was not limited 
to cells that were arrested at a particular point in the cell cy- 
cle  nor  to  cells  that  have  withdrawn  from the  cell  cycle. 
These data indicate that if TGF-l~-induced hypertrophy was 
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Figure Z  The cell cycle dependence of TGF-~-induced cellular 
hypertrophy was assessed by simultaneous  analysis of FALS and 
cellular DNA content by flow microfluorimetry. Data analyses in- 
volved  standard  curve  fitting  to identify  Gl  and  (32 peaks  us- 
ing software provided on the Epics V, calculation of peak means 
(+SD), setting  of gating windows on DNA histograms based on 
these calculations  (peak  means  ±  2 SD were used), followed by 
calculation of the mean (+ SE) FALS values for that population. 
Cells were treated with either vehicle or TGF-~ at the concentra- 
tions indicated  for 3 d. Additional experimental details were iden- 
tical  to those  described  for Fig.  5.  Comparisons  are  between 
control and TGF-~-treated cells  identified  as being either in the 
Go-G~ phase or the (;2 phase of the cell cycle based on examina- 
tion of DNA histograms. Relative cell size of TGF-O is expressed 
as a percentage of the corresponding cells (in the same phase of 
the cell cycle) from vehicle-treated controls. Means  +  SD (n  = 
3) are shown. 
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anism that does not  involve growth arrest and  subsequent 
hypertrophy of cells at a  particular point in the cell cycle. 
However, an alternative possibility that must be considered 
is that TGF-13-induced  hypertrophy may not be a direct con- 
sequence  of growth  inhibition  but  simply occurs  concur- 
rently due to some additional effect of TGF-I3 distinct from 
growth inhibition. 
TGF-~  -induced Hypertrophy of  Q  uiescen t Sm  oo  th 
Muscle Cells in a Defined SFM 
To determine whether TGF-[3 could induce hypertrophy in 
the  absence  of  significant  growth  inhibition,  cells  were 
plated in medium containing 10% FCS for 24 h, switched to 
SFM for 5 d to induce quiescence,  and treated with either 
100 pM TGF-I3 or vehicle control for 3 d, and relative cell 
size was assessed by flow cytometric determination of FALS. 
Results  showed  a  significant  increase  in  FALS  in  TGF- 
I~-treated cultures  as compared to vehicle-treated controls 
(Fig. 8), whereas no detectable change in the fraction of cells 
in the S phase of the cell cycle was apparent by either flow 
microfluorimetric analysis or by [3H]thymidine autoradiog- 
raphy.  [3H]thymidine-labeling  indices  (1-h pulse)  from  a 
representative experiment, were 0.9  +  0.3%  at the time of 
initiation of treatment and 0.6  +  0.4%  and  1.0  +  0.5%  (P 
> 0.05) in TGF-[I and vehicle-treated control groups, respec- 
tively, at 48 h after initiation of treatment, and were typically 
<2 % for all groups in replicate experiments. Consistent with 
these data, no significant changes in cell number were ob- 
served over the 3-d duration of these experiments.  Signifi- 
cant  increases  in  FALS  were  observed  in  TGF-13-treated 
cells in each of four independent experiments. However, for 
reasons that are not clear, the percent increase in mean FALS 
was quite variable between experiments ranging from 8 to 
23 % (P < 0.01 in all cases, paired t test). Results demonstrate 
that  TGF-13 can  induce  hypertrophy  of quiescent  smooth 
muscle cells in a defined SFM,  although the magnitude of 
the cellular hypertrophy is considerably  less than that ob- 
t- 
t- 
O 
o  ,p- 
x 
JO 
E 
m 
~5' 
.t  ~  ~: 
Con  ,t~ /  GFI3 
•  l  )=  I  "=IL~  t=l-I 
[  1  I'  ,J  "~,= "% 
~1..  [~1. i  ,~1  (  '~-~  % 
Z  I'~,_., ~,..~ .~  ~,.~. ~ ......... 
!  -:~  .  ...  ,.t,~._..~:.£.~:.p,.,~_.~A_.~=._.  ~ ~ 
@ 
0  Relative  Cell SIze 
FALS 
Figure 8. TGF-I~-induced hypertrophy of smooth muscle cells in 
a defined SFM.  Cells were plated at 3  x  103 cells/cm 2 in SFM 
(see Materials and Methods) containing 10% FCS for 24 h to pro- 
mote cell attachment and spreading and then switched to SFM alone 
for 5 d (with a media change at 2.5 d) to induce quiescence. Under 
these conditions,  pH]thymidine  labeling indices (1-h pulse) were 
typically <2 %. Cells were then treated with 100 pM TGF-13  or vehi- 
cle for 3 d and relative cell size (i.e., FALS) and cellular DNA con- 
tent (not shown) determined  by flow microfluorimetry. 
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Figure 9.  Cell cycle distribution  of rat aortic  smooth muscle cell 
cultures after treatment with 100 pM TGF-I~  (lower  panel) or vehi- 
cle for 9 d. Cells were plated at 3 x  103 cells/cm 2 in Medium 199 
containing  10% FCS for 24 h, switched to Media  199 containing 
5 % FCS, and treated with either 100 pM TGF-13  or vehicle for 9 d 
with media changes and readdition of TGF-13  or vehicle at 2-d inter- 
vats. Cells were then harvested, and FALS (not shown) and cellular 
DNA content were analyzed by flow microfluorimetry as described 
in Materials and Methods. A minimum of 10,000 cells were ana- 
lyzed per sample. 
served in the presence of serum.  However, TGF-13 was ex- 
tremely potent in inducing hypertrophy under these condi- 
tions showing maximal effects with concentrations as low as 
2  pM (data not shown). 
Effects of  Long-term  Treatment with TGF-~ 
on Cellular DNA Content 
An  interesting  observation  in  earlier  growth  inhibition 
studies was what appeared to be a disproportionate fraction 
of cells in the G2 phase of the cell cycle relative to the frac- 
tion of cells in S phase in TGF-13-treated cultures as com- 
pared to controls. This was of interest, since it is consistent 
with development of polyploidy, which is known to occur in 
association with smooth muscle cell hypertrophy in vivo (10, 
23, 24, 30).  However, a major difficulty in these short-term 
experiments in sparse cultures was the high frequency of cy- 
cling cells and the inability to distinguish cycling cells in G2 
from tetraploid cells.  To at least partially circumvent this 
complication,  subsequent  experiments were  done  using  a 
treatment period of 9 d, which had two advantages. First, in 
9-d experiments both control  and  TGF-13-treated cultures 
grew to saturation density at which cell replication was con- 
siderably reduced in both groups. Second, long-term experi- 
ments  permitted  examination  of the  cumulative effects of 
TGF-I~ that  might not be detectable  in  short-term experi- 
ments (e.g., the gradual accumulation of cells at a particular 
point in the cell cycle). 
In these experiments, cells in Medium 199 containing 5 % 
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Figure 10. Representative cell cycle histograms from experiments exploring the growth response of putative tetraploid cells after removal 
of TGF-I~  and addition of media containing 10% FCS. Cells were treated with TGF-I3  (100 pmol) or vehicle in media containing 5 % FCS 
for 9 d as described  in the legend to Fig. 9, washed with fresh media,  and then grown in Medium  199 containing  10% FCS. Samples 
were harvested for flow cytometric analysis of cellular DNA content (as described in Materials and Methods) 24 h later. (A and B) DNA 
histogram (at two different scales) from ceils treated with vehicle during the initial 9-d treatment period;  (C and D) histogram (again at 
two scales) from cells treated with TGF-13. An expanded scale is used in B and D to better visualize cells with >4c DNA content, which 
are present in relatively low abundance. A total of 15,000 cells were analyzed in each sample. A summary of the results of these experiments 
is presented in Fig.  11. 
FCS were treated with 100 pM TGF-13 or vehicle for 9 d and 
cellular DNA content assayed by flow microfluorimetry (Fig. 
9).  Results demonstrated a large fraction of cells in the G2 
phase of the cell cycle in TGF-I~ (G2%  =  26.5  ___  1.6; mean 
_  standard  error  of  four  experiments)  as  compared  to 
vehicle-treated control cultures (G2 %  =  7.6  +  0.5), despite 
an extremely low fraction of cells in the S phase of the cell 
cycle based on examination of flow cytograms (see Fig. 9), 
or  as  measured  by  [3H]thymidine autoradiography.  These 
latter analyses showed 2.3  +  0.4%  and  16.4  -1- 2.1%  cells 
in  S  phase  for TGF-13 and  vehicle-treated control  groups, 
respectively. Observations are consistent with either arrest of 
cells  in  the  G2  phase  of the  cell  cycle  (4c  DNA,  but  2n 
chromosome number)  or development of true  tetraploidy 
(i.e.,  4c  DNA,  4n  chromosome  number  in  the  resting, 
G0-GI,  phase  of the  cell  cycle).  The  fact that  there  is  a 
significant increase in the fraction of cells with greater than 
tetraploid DNA in TGF-13-treated cultures as compared to 
controls (see Fig.  11, 0 time point), and that this fraction in- 
creases after removal of TGF-13 and  restimulation of cells 
with medium containing 10% FCS (Figs.  10 and 11) provide 
strong evidence that TGF-13 has induced formation of tetra- 
ploid SMC. 
Note that in the experiment presented in Figs.  10 and  11 
the overall proliferative response of cells was quite  small 
since  cells  were postconfluent  and  exhibited  considerable 
contact inhibition of growth.  To increase the magnitude of 
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Figure  11.  Growth  response  of tetraploid  cells  after removal of 
TGF-I~ or vehicle and growth in media containing 10% FCS. Addi- 
tional experimental details are presented in Fig. 10. The fraction of 
cells with >4c DNA content was calculated by determining the frac- 
tion of cells with DNA contents between the G2 mean plus 2 SD 
and the point at which the 8c peak returned to baseline. Each point 
represents the mean +  SD of at least three experimental samples. 
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I~-treated cells, experiments were also done in which cells 
were treated for 9 d with TGF-13 or vehicle, and then washed 
and  passaged  into  standard  media  containing  10%  FCS. 
Consistent with the results above, flow cytometric analysis 
of cellular DNA content 48 h after passage demonstrated a 
45%  increase in cells with greater than 4c DNA in TGF- 
I~-treated cells as compared to controls, supporting the idea 
that TGF-I]  treatment induces formation of tetraploid cells 
which are capable of further DNA replication. 
Discussion 
The initial objective in these studies was to characterize the 
nature of TGF-13-induced growth inhibition in cultured rat 
aortic smooth muscle cells. Consistent with previous reports 
on bovine aortic smooth muscle cells (3), TGF-I] was a po- 
tent inhibitor of serum-induced growth of rat aortic smooth 
muscle cells showing an EDso and maximal effects at con- 
centrations of 2  and 20 pM,  respectively. TGF-I]-induced 
growth inhibition was associated with a marked increase in 
the cell cycle transit time in cells that continue to replicate 
in the presence of TGF-13, as well as the appearance of a sub- 
fraction of cells which did not replicate their DNA during 
a  72-h  [3H]thymidine-labeling period.  Whereas  it  is  not 
clear whether these latter cells have actually withdrawn from 
the cell cycle, it is clear that they must replicate at an ex- 
tremely low rate. Roberts et al. (27) have reported a similar 
increase in cell cycle time for human lung carcinoma A-549 
cells treated with TGF-~, although these data were based on 
determinations of doubling times and did not definitively as- 
sess the possible contributions of TGF-13-induced cell cycle 
withdrawal or increased cell turnover. Our flow cytometric 
analyses  showed  an  increased fraction of cells  in  the  G~ 
phase of the cell cycle and a reduced fraction in S phase con- 
sistent with arrest in G], as reported previously by Heimark 
et al. (19a) for TGF-13-induced growth arrest in bovine en- 
dothelial cells. However, in the present study, TGF-~ treat- 
ment was also associated with the accumulation of cells in 
the G2 phase of the cell cycle suggesting that at least some 
cells may be growth arrested in G2, although it appears that 
the rate at which cells accumulate in G2 is quite low. In any 
event, it appeared that the major effect of TGF-I] in inhibiting 
smooth muscle cell growth was due to an increase in cell cy- 
cle time rather than complete growth arrest at a particular 
point in the cell cycle. 
TGF-I~-induced growth inhibition was associated with de- 
velopment of marked cellular hypertrophy as  well as the 
gradual accumulation of cells in the G2 phase of the cell cy- 
cle in the virtual absence of cells in S phase. Development 
of cellular hypertrophy did not require withdrawal of cells 
from the cell cycle in that all cells appeared to be hyper- 
trophied (see histograms, Fig. 4), and by far the majority of 
cells, if not all, continue to cycle in the presence of TGF-13 
although at a reduced rate (Table I). Furthermore, develop- 
ment of  hypertrophy did not require arrest of cells at a partic- 
ular point in the cell cycle in that both cells in Gm as well as 
cycling cells in G2 were hypertrophied as compared to the 
corresponding  cells  in  vehicle treated  controls  (Fig.  7). 
Thus, hypertrophy was present irrespective of the position in 
the cell cycle. Since it is well established that serum evokes 
a large increase in cellular protein synthesis as part of the 
hypertrophic component of the proliferative response (5), 
one interpretation of these data is that TGF-~-induced cellu- 
lar hypertrophy is the result of an increase in cell cycle transit 
time  such  that  the  hypertrophic component of cell  cycle 
progression is prolonged and cells attain a larger mass. That 
is, TGF-~ may selectively inhibit serum-stimulated increases 
in DNA replication, while having little or no effect  on serum- 
induced increases in protein synthesis. Consistent with this 
idea,  Like  and  Massague  (20)  demonstrated  that  TGF-[3 
completely  blocked  serum  or  epidermal  growth  factor- 
induced increases in DNA replication in MvlLu mink lung 
epithelial cells, but did not block increases in $6 kinase ac- 
tivity, which has been implicated in the control of increased 
protein synthesis during cell cycle progression (9). Whether 
TGF-~-induced hypertrophy is indeed the result of selective 
inhibition of a subcomponent of those proliferative signals 
associated  with  DNA  replication  and  cell  division,  and 
whether this is a generalized property of growth inhibitors 
that increase To, remains to be determined. 
An alternative possibility is that TGF-I]-induced hyper- 
trophy represents a direct response to TGF-[3 that is indepen- 
dent of growth inhibition. Observations that TGF-I~ could in- 
duce hypertrophy of quiescent smooth muscle cells under 
serum free conditions support this idea. However, although 
TGF-I~ was extremely potent in causing hypertrophy under 
serum-free conditions (maximal effects were observed with 
concentrations as low as 2 pM),  its efficacy was quite low 
eliciting a maximal increase in FALS of only 8-23 % over 
control as compared with the 35-50% increase observed in 
serum containing experiments. The hypertrophic response 
elicited by TGF-I~ in SFM, may be similar to that evoked by 
angiotensin II in these cells. This contractile agonist induces 
hypertrophy, as well as apparent polyploidy of cultured rat 
aortic smooth muscle cells grown under serum-free condi- 
tions  (18),  consistent  with the hypothesis that  contractile 
agonists can directly stimulate smooth muscle cell hyper- 
trophy. The high potency and low efficacy of TGF-13 as a con- 
tractile agonist (6) would be consistent with its modest ability 
to directly stimulate cell hypertrophy. Thus, it is possible that 
part of the hypertrophic response observed in the presence 
of serum is due to direct hypertrophic effects of TGF-13. How- 
ever, it is also possible that the cellular responses elicited un- 
der these two conditions are unrelated and occur by indepen- 
dent mechanisms. 
An interesting observation in the present study was that 
prolonged TGF-I] treatment was associated with a marked in- 
crease in the fraction of cells in the G2 phase of the cell cy- 
cle in the absence of  a significant fraction of  ceils undergoing 
DNA  replication,  consistent  with  either  development of 
tetraploidy or arrest of diploid cells in the Ge phase of the 
cell cycle. Observations of a significant fraction of cells with 
octaploid DNA content in TGF-I~-treated cultures as well as 
the appearance of a significant fraction of cycling cells with 
greater than tetraploid DNA upon removal of TGF-I~ and re- 
stimulation with  10%  FCS containing media strongly sug- 
gest that chronic treatment with TGF-13 has induced forma- 
tion of tetraploid cells. However, our data do not exclude the 
possibility that at least some of the cells in the 4n peak fol- 
lowing TGF-I~ treatment represent cells arrested in the G2 
phase of the cell cycle. It should be noted that these two 
phenomenon may not be clearly separable experimentally 
and may be causally related. For example, TGF-I~ may in- 
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prolonged may result in withdrawal from the cell cycle from 
G2  and  tetraploidy.  Consistent  with this  idea,  Zaitsu  and 
Kimura  (34)  found that  3Y1  tsF121  cells,  a  temperature- 
sensitive mutant which arrests in either Gt or G2 at the non- 
permissive temperature,  lose the ability to complete mitosis 
after prolonged G2 arrest.  Although many examples of G2 
arrest have been reported in the literature,  most of these in- 
volve irradiation or chemical treatment of cells (26, 28, 34), 
and this is the first demonstration, to our knowledge, of in- 
duction of (32 arrest  and polyploidy by  a naturally  occur- 
ring,  chemically  defined  substance.  The  fact  that  the  G2 
cells were mononucleate (based on visual observation and 
flow cytometric analysis) indicates that neither karyokinesis 
or cytokinesis  occurred.  These data  also  strongly  suggest 
that the observed polyploidy is not the result of cell fusion, 
since in this case one would expect to see multinucleate cells. 
The mechanisms whereby TGF-I3 might inhibit progression 
through  G2  are  not  known.  Obvious  possibilities  are  that 
TGF-13 may disrupt cytoskeletal components or inhibit  syn- 
thesis of G2 specific proteins (26) necessary for mitosis, al- 
though  direct  evidence  for  either  of  these  is  currently 
lacking. 
Although no direct evidence is available  implicating a role 
for TGF-I~ in the hypertrophic  response of smooth muscle 
cells in chronic hyptertension, the similarities in the growth 
responses observed in the present in vitro studies and that 
observed in vivo (10, 23, 24, 30) make it is tempting to specu- 
late that TGF-I~ might play some role. This might involve re- 
lease of TGF-I3 from platelets (2) adherent  to a vessel wall 
damaged  by  increased  hemodynamic  stresses  associated 
with hypertension (31).  Alternatively,  TGF-I~ might be de- 
rived from endothelial cells,  smooth muscle cells, or acti- 
vated macrophages which contain TGF-I3 mRNA (1, 21). 
In summary,  results of the present studies provide addi- 
tional support for the hypothesis that TGF-13 may be an im- 
portant regulator  of smooth muscle cell growth and suggest 
that one mechanism whereby cellular hypertrophy  and poly- 
ploidy can occur in cells is by alterations  in the response to 
serum mitogens by potent growth inhibitors such as TGF-I3. 
Further  studies will be required  to determine:  (a) whether 
development of cellular hypertrophy  is a common response 
of many cell types to certain growth inhibitors;  (b) the mech- 
anisms of action of TGF-13 in inhibiting cell proliferation, 
and inducing cellular hypertrophy  and polyploidy;  (c) the 
relationship  between  G2  arrest  and  development  of poly- 
ploidy; and (d) whether TGF-I3 is involved in mediation of 
vascular smooth muscle hypertrophy  in vivo. 
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